Overview of Recent Progress in Protein-Expression Technologies for Small-Molecule Screening
DEL Overview
Screen Hundreds of Billions of Compounds Against Your Drug Discovery Target X-Chem’s DNA-encoded library (DEL) technology is deployed for and by clients...
X‑Chem and Structural Genomics Consortium Enter Into Collaboration to Unlock the Human Proteome and Promote Open Science
WALTHAM, Mass.; Sept. 28, 2023 (Business Wire) – X-Chem, a global leader in innovative drug discovery services, and the Structural...
LEO Pharma and X‑Chem Enter Into Discovery Research Agreement
Multi-target Collaboration to Focus on Identification of Novel Small Molecules for Anti- inflammatory Applications BALLERUP, Denmark, and WALTHAM, Mass., US;...
BioDuro-Sundia and X‑Chem Enter Partnership to Launch DEL Services in China for the Discovery of New Small Molecule Drugs
Shanghai, August 8 2022 – BioDuro-Sundia, an industry-leading drug discovery, development and commercial service CRDMO backed by Advent International, and...
DELability – Protein Assessment for DEL Screening
Over the last 5 years, biopharma has fully embraced the use of DNA-encoded libraries (DELs) for hit identification for all...
X‑Chem Announces Strategic Collaboration with Astellas Pharma Across Multiple Therapeutic Areas
WALTHAM, Mass. – March 20 2017 – X-Chem, Inc. (X-Chem), a privately held biotechnology company applying its innovative drug discovery capabilities to the generation of novel small molecule therapeutics, announced the signing of a broad drug discovery collaboration with Astellas Pharma Inc. (Astellas). The collaboration will enable the discovery of novel lead compounds for complex drug targets of interest to Astellas from X-Chem’s growing collection of DNA-encoded DEX™ libraries containing over 120 billion compounds. This new partnership is X-Chem’s most expansive first-time alliance with a pharmaceutical company, and is aimed at tackling hard-to-drug targets across multiple therapeutic areas at Astellas.
X‑Chem Announces Publication in Nature
WALTHAM, Mass. –April 26, 2017 – X-Chem, Inc. (X-Chem), a privately held biotechnology company applying its innovative DNA-encoded library platform (DEXTM) to the discovery of the next generation of small molecule therapeutics, announced today a publication in Nature. The article, co-authored by scientists from AstraZeneca Inc. and Heptares, Inc., describes the crystal structure of protease-activated receptor 2 (PAR2) complexed with an antagonist that competes with the tethered natural ligand, and a second antagonist that binds to a hitherto unknown allosteric site on the seven transmembrane-domain receptor.
Truncations, Side Products and Truth in Labeling for DNA-Encoded Libraries: A Cautionary Tale
Did you ever search a library catalog, dutifully note the location of a book that is allegedly not checked out,...